View ValuationAdaptive Biotechnologies 将来の成長Future 基準チェック /16Adaptive Biotechnologies利益と収益がそれぞれ年間50.5%と15.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に4.5% 50.3%なると予測されています。主要情報50.5%収益成長率50.31%EPS成長率Life Sciences 収益成長20.1%収益成長率15.2%将来の株主資本利益率4.53%アナリストカバレッジGood最終更新日17 Jun 2026今後の成長に関する最新情報お知らせ • May 08+ 1 more updateAdaptive Biotechnologies Corporation Raises Revenue Guidance for the Full Year of 2026Adaptive Biotechnologies Corporation Raised revenue guidance for the full year of 2026. For the period, the company expects full year revenue for the MRD business to be between $260 million and $270 million, updated from the previous range between $255 million and $265 million.お知らせ • Feb 06Adaptive Biotechnologies Corporation Provides Earnings Guidance for 2026Adaptive Biotechnologies Corporation provided earnings guidance for 2026. For the period, Adaptive Biotechnologies expects full year revenue for the MRD business to be between $255 millionand $265 million. No revenue guidance is provided for the Immune Medicine business.お知らせ • Nov 06Adaptive Biotechnologies Corporation Updates Earnings Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updates earnings guidance for the full year 2025. The company expected full year revenue for the MRD business to be between $202 million and $207 million, updated from the previous range between $190 million and $200 million. No revenue guidance is provided for the Immune Medicine business.お知らせ • Aug 06Adaptive Biotechnologies Corporation Updates Financial Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updated financial guidance for the full year 2025. For the year, the company expects full year revenue for the MRD business to be between $190 million and $200 million, updated from the previous range between $180 million and $190 million. No revenue guidance is provided for the Immune Medicine busine.お知らせ • May 02Adaptive Biotechnologies Corporation Revises Earnings Guidance for 2025Adaptive Biotechnologies Corporation revised earnings guidance for 2025. For the period, the company expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.お知らせ • Apr 03Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.すべての更新を表示Recent updatesBoard Change • Jun 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 30Adaptive Biotechnologies Corporation Reports New Data Reinforcing Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and ResearchAdaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO and EHA this year continue to reinforce clonoSEQ’s role in modern hematologic oncology care — as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Across hematologic malignancies, these studies highlight how MRD measured by clonoSEQ continues to be broadly incorporated into both research and clinical practice: Multiple myeloma: Highly sensitive MRD testing continues to demonstrate depth and durability of response across novel therapies, including follow-up data from the inMMyCAR trial of CAR T-cell therapy and bispecific antibody data from MONUMENTAL-3. In addition, a final analysis from the CEPHEUS trial, the basis for the first-ever FDA approval based on an MRD endpoint, showed higher rates of sustained MRD negativity in patients treated with quadruplet regimen daratumumab plus VRd (bortezomib, lenalidomide, and dexamethasone). Chronic lymphocytic leukemia (CLL): MRD is being incorporated into decisions around therapy duration and discontinuation in studies including BOVen-?MRD400 and venetoSTOP, the latter demonstrating that personalized venetoclax treatment duration based on uMRD5 status leads to durable treatment-free remissions. Acute lymphoblastic leukemia (ALL): In a Phase 2 study evaluating dose-adjusted EPOCH with rituximab and tafasitamab, MRD assessment with clonoSEQ continues to outperform flow cytometry in detecting residual disease and predicting patient outcomes and can be used to assess disease burden in cerebrospinal fluid. Lymphoma: clonoSEQ leverages sensitivity and specificity to support MRD testing in real-world and clinical trial settings across multiple major lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). At EHA this year, new data further expand the evidence base for highly sensitive, next-generation sequencing–based MRD assessment and underscore the increasingly global nature of clonoSEQ’s reach and impact. Across Europe, growing momentum behind MRD-guided care is being driven, in part, by increasing biopharmaceutical industry investment in interventional studies that incorporate MRD into treatment decisions. clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL. clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR).お知らせ • May 08+ 1 more updateAdaptive Biotechnologies Corporation Raises Revenue Guidance for the Full Year of 2026Adaptive Biotechnologies Corporation Raised revenue guidance for the full year of 2026. For the period, the company expects full year revenue for the MRD business to be between $260 million and $270 million, updated from the previous range between $255 million and $265 million.お知らせ • Apr 27Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 05, 2026Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 05, 2026.お知らせ • Apr 16Adaptive Biotechnologies Corporation to Report Q1, 2026 Results on May 05, 2026Adaptive Biotechnologies Corporation announced that they will report Q1, 2026 results After-Market on May 05, 2026お知らせ • Feb 06Adaptive Biotechnologies Corporation Provides Earnings Guidance for 2026Adaptive Biotechnologies Corporation provided earnings guidance for 2026. For the period, Adaptive Biotechnologies expects full year revenue for the MRD business to be between $255 millionand $265 million. No revenue guidance is provided for the Immune Medicine business.お知らせ • Jan 23Adaptive Biotechnologies Corporation to Report Q4, 2025 Results on Feb 05, 2026Adaptive Biotechnologies Corporation announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 05, 2026Board Change • Jan 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Dec 13Independent Director recently sold €316k worth of stockOn the 10th of December, Robert Hershberg sold around 23k shares on-market at roughly €13.74 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.1m more than they bought in the last 12 months.Board Change • Dec 08Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 06Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual MeetingAdaptive Biotechnologies Corporation announced growing interventional use of its clonoSEQ test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive's clonoSEQ test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care. The presentations below show how investigators are applying clonoSEQ MRD results to tailor treatment intensity or duration with greater precision. Multiple Myeloma (MM). A total of 32 abstracts will be presented (31 MM, one smoldering MM), with a focus on MRD assessment of treatment response, real-world data demonstrating the link between MRD status and clinical outcomes, and several studies describing how clonoSEQ MRD Results are being used to guide treatment decisions. A presentation focused on MRD dynamics in the phase III AURIGA study of 200 newly diagnosed MM patients demonstrated that deep MRD responses and sustained MRD negativity correlated with improved progression free survival. The study shows that use of intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates (oral presentation, abstract 97). Non-Hodgkin Lymphoma (NHL). Fifteen abstracts in NHL will be presented, focusing on use of MRD to better understand depth of response and to guide therapy.Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.063 (vs US$0.22 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.063 (up from US$0.22 loss in 3Q 2024). Revenue: US$94.0m (up 102% from 3Q 2024). Net income: US$9.55m (up US$41.6m from 3Q 2024). Profit margin: 10% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 06Adaptive Biotechnologies Corporation Updates Earnings Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updates earnings guidance for the full year 2025. The company expected full year revenue for the MRD business to be between $202 million and $207 million, updated from the previous range between $190 million and $200 million. No revenue guidance is provided for the Immune Medicine business.Board Change • Oct 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 16Adaptive Biotechnologies Corporation to Report Q3, 2025 Results on Nov 05, 2025Adaptive Biotechnologies Corporation announced that they will report Q3, 2025 results After-Market on Nov 05, 2025お知らせ • Aug 06Adaptive Biotechnologies Corporation Updates Financial Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updated financial guidance for the full year 2025. For the year, the company expects full year revenue for the MRD business to be between $190 million and $200 million, updated from the previous range between $180 million and $190 million. No revenue guidance is provided for the Immune Medicine busine.お知らせ • Jul 16Adaptive Biotechnologies Corporation to Report Q2, 2025 Results on Aug 05, 2025Adaptive Biotechnologies Corporation announced that they will report Q2, 2025 results After-Market on Aug 05, 2025お知らせ • Jun 30+ 5 more updatesAdaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 3000E Value IndexAdaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 3000E Value Indexお知らせ • May 30Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid CancersAdaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ®? test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. Data to be presented at ASCO: Presentation Type and Number Title Presentation Timing B-Cell Acute Lymphoblastic Leukemia. Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, Sunday, June 1, 6540 cyclophosphamide, and doxorubicin (DA-EPOCH) + rituximab (R) + tafasitamab (tafa) for adults 9 a.m.-12 p.m. CDT with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL). Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute Sunday, June 1, 6543 lymphoblastic leukemia 9 a.m.-12p.m. CDT Multiple Myeloma: Multiple Myeloma: Primary endpoints of Tuesday, June 3, 7501 lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple.お知らせ • May 02Adaptive Biotechnologies Corporation Revises Earnings Guidance for 2025Adaptive Biotechnologies Corporation revised earnings guidance for 2025. For the period, the company expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.お知らせ • Apr 30Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025. Location: entirely via the internet, United Statesお知らせ • Apr 11Adaptive Biotechnologies Corporation to Report Q1, 2025 Results on May 01, 2025Adaptive Biotechnologies Corporation announced that they will report Q1, 2025 results After-Market on May 01, 2025お知らせ • Mar 11Adaptive Biotechnologies Corporation Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell LymphomaAdaptive Biotechnologies Corporation announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. The assay leverages the same powerful technology as prior versions, detecting MRD by reading the full immune receptor sequence of the malignant B cells rather than relying on individual point mutations. Maintaining this proprietary approach enables improvements in sensitivity while preserving the exquisite specificity that minimizes risk of overtreatment due to false positives. The enhanced assay was previously made available for research use in November 2023 and is already being incorporated into both biopharma-sponsored and investigator-initiated prospective trials. Data generated using this assay and presented at ASH 2024 by Bond and colleagues demonstrated that in patients for which MRD was assessed by clonoSEQ, MRD negativity post-cycle six was highly prognostic of progression-free survival. clonoSEQ is the first and only DLBCL MRD test available for clinical use. Having secured Medicare coverage for clonoSEQ in DLBCL in July of 2022, Adaptive has since provided MRD testing for more than 2,800 DLBCL patients and was used to manage and inform patient care by over 640 providers in 2024 alone. The New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) recently approved the enhanced version of the clonoSEQ ctDNA assay for the detection and monitoring of MRD in patients with DLBCL. This comes on the heels of the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas, which included language recommending ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of first-line treatment. Because DLBCL outcomes can vary widely following frontline treatment, the ability of MRD results to accurately risk stratify patients in this setting is critical, as an MRD test can help clinicians differentiate a likely cure from an impending relapse. As the number of clinical trials in DLBCL exploring novel MRD-directed treatment consolidation strategies to reduce relapse rates grows, the role for clonoSEQ as a highly sensitive and specific ctDNA-based test will continue to expand.お知らせ • Jan 23Adaptive Biotechnologies Corporation to Report Q4, 2024 Results on Feb 11, 2025Adaptive Biotechnologies Corporation announced that they will report Q4, 2024 results After-Market on Feb 11, 2025Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 09Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in Mrd Testing with Clonoseq and Its Impact on Blood Cancer Treatment DecisionsAdaptive Biotechnologies Corporation announced new data demonstrating the impact of measurable residual disease assessment using Adaptive’s next-generation sequencing-based clonoSEQ test in blood cancer clinical care and drug development. The data are featured in more than 65 abstracts being presented at the 66th Annual Meeting of the American Society of Hematology, taking place December 6-10 in San Diego. Phase 3 data from the ECOG-ACRIN EA4151 trial indicate that autologous hematopoietic cell transplantation (auto-HCT) may not provide additional benefit for mantle cell lymphoma patients in first complete remission who have undetectable minimal residual disease at a sensitivity of 10?6. The findings will be presented in a late-breaking abstract titled, Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma Patients (pts) in First Complete Remission with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial (Abstract LBA6). Patients in CR with uMRD at 10?6 sensitivity from peripheral blood were randomized to receive either auto-HCT plus three years of maintenance rituximab or MR alone. Interim analysis, with a median follow-up of 2.7 years, showed no significant difference in overall survival between the two groups, suggesting that auto-HCT may be unnecessary for patients achieving deep remission as measured by highly sensitive MRD assessment. Data from the FELIX study indicate that achieving deep molecular remission, defined as MRD levels below 10?6, correlates with improved outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel. These findings were presented in an oral session titled Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes (Abstract 963). The study found that 84% of treatment responders who had a clonoSEQ MRD test, achieved MRD <10?6. This result was associated with more durable responses, and higher event-free survival and OS rates than those observed in patients with MRD =10-4 and between 10-4 and 10-6. Additional Key clonoSEQ Data Presented at the Meeting: Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731 (Abstract1). This Phase 3 randomized trial evaluated the addition of blinatumomab to standard chemotherapy in pediatric patients with newly diagnosed standard-risk B-ALL with average or higher risk of relapse. In the SR average cohort, patients that were MRD positive by clonoSEQ were randomized to receive standard chemotherapy with or without blinatumomab. The study found that incorporating blinatumomab significantly improved disease-free survival compared to chemotherapy alone, establishing a new treatment standard for this patient population. Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation (Abstract 363). This study identified 49 newly diagnosed multiple myeloma patients treated with a quadruplet regimen followed by autologous stem cell transplantation who experienced MRD progression as assessed by clonoSEQ, or disease progression as defined by the International Myeloma Working Group. The median time from MRD progression to IMWG-defined disease progression was 10.1 months, supporting that rising MRD levels are an early indicator of impending clinical relapse in MM patients. Minimal Residual Disease-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (Abstract 1010). This Phase 2 study evaluating the use of venetoclax and obinutuzumab in treatment-naïve CLL patients found that those achieving undetectable MRD (<10?6) after nine cycles could discontinue therapy early. These patients had progression-free survival comparable to those who completed the standard 12 cycles, demonstrating the feasibility of MRD-guided treatment duration to minimize therapy exposure without compromising efficacy.お知らせ • Oct 10Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024Adaptive Biotechnologies Corporation announced that they will report Q3, 2024 results After-Market on Nov 07, 2024お知らせ • Aug 29Adaptive Announces IVDR Certification for clonoSEQ® in European UnionAdaptive Biotechnologies Corporation announced that clonoSEQ® has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). The medical diagnostics field has experienced significant technological advancement in recent years, leading the EU to replace its previous regulatory framework, the In Vitro Diagnostics Directive (IVDD), with a more stringent set of standards for quality and safety, known as IVDR. Adaptive worked with EU notified body BSI to complete the certification process and transition the company’s IVDD CE-marked product, the clonoSEQ Assay B-Cell Reagent Set, to this new regulation. clonoSEQ is now the first and only test to receive IVDR certification for the detection of minimal residual disease (MRD) in lymphoid malignancies. clonoSEQ’s intended use under IVDR is broad in scope, allowing for assessment of MRD status and changes in disease burden during and after treatment in patients diagnosed with B-cell malignancies. As MRD testing becomes increasingly adopted in patient care, clonoSEQ provides a powerful and dynamic way to measure risk status for patients with lymphoid malignancies and yields real-time insights into disease progression that can help oncologists provide a more personalized treatment approach. In addition to clinical use, clonoSEQ is the test of choice for MRD assessment among drug developers performing clinical research in hematologic malignancies. The assay has been included in global, label-enabling studies for a multitude of therapies approved by the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) over the past several years. IVDR certification allows Adaptive to meet the clinical trial regulations for testing EU subjects’ samples, and sponsors can seamlessly send clinical trial subjects’ samples from the EU to Adaptive’s Seattle, Washington laboratory. clonoSEQ is well-established as a leading tool in blood cancer MRD assessment, supported by more than 150 peer-reviewed publications and used clinically by more than 3,700 clinicians over the past year. Furthermore, clonoSEQ MRD is currently being utilized in more than 160 active biopharma-sponsored trials. clonoSEQ is available locally in the EU to oncologists through technology transfer partnerships with major academic laboratories. clonoSEQ testing can currently be performed in France by Centre Hospitalier Universitaire (CHU) Toulouse, in Italy by Hospital of Bologna, in Spain by Hospital 12 du Octubre, and in Germany by HPH laboratory. Additional technology transfer partnerships are expected to launch in the EU and surrounding markets later in 2024.Board Change • Aug 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 12Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024Adaptive Biotechnologies Corporation announced that they will report Q2, 2024 results After-Market on Aug 01, 2024お知らせ • Apr 28Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024, at 09:00 Pacific Standard Time. Agenda: To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders. The two nominees for election to the board of directors are Peter Neupert and Michelle Griffin; to approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement; to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; and to conduct any other business properly brought before the meeting or any adjournments thereof.お知らせ • Apr 19Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024Adaptive Biotechnologies Corporation announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Apr 04Adaptive Biotechnologies Corporation Announces CFO ChangesAdaptive Biotechnologies Corporation announced that Tycho Peterson will depart the company as CFO. Kyle Piskel, the company's Principal Accounting Officer, will succeed Peterson as full-time CFO. Piskel served as the company's interim CFO from February to June 2022.お知らせ • Apr 03Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.お知らせ • Jan 30Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024Adaptive Biotechnologies Corporation announced that they will report Q4, 2023 results After-Market on Feb 14, 2024お知らせ • Dec 05Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual MeetingAdaptive Biotechnologies Corporation together with its collaborators will present data from more than 30 abstracts demonstrating the actionability of Adaptive's next-generation sequencing (NGS)-based clonoSEQ test in assessing minimal residual disease (MRD) in blood cancer patients at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California. clonoSEQ is the only U.S. Food and Drug Administration (FDA)-cleared test to detect MRD in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ testing for other lymphoid malignancies, includingdiffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL) is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, Washington. Minimal residual disease – also referred to as measurable residual disease – is one of the strongest predictors of outcomes in blood cancers and routine testing provides a personalized way to track a patient’s individual response to treatment and inform shared decision-making to optimize care. In addition to clinical use, MRD testing is widely used in drug development to get an early read on efficacy to inform patient stratification and increasingly as a trial endpoint. Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured in a late-breaking presentation, eight oral presentations and 24 posters across lymphoid malignancies. Studies will be presented demonstrating the clinical actionability of MRD testing across disease states. Notably, data illustrating the prognostic value of clonoSEQ MRD assessment using peripheral blood in MM and from circulating tumor DNA (ctDNA) in DLBCL will also be presented. Additionally, biopharmaceutical companies and other investigators will share data from 13 studies using clonoSEQ as an endpoint to measure deep responses during or after therapy, including novel treatment regimens such as CAR T-cell therapies and bispecifics. To advance biopharmaceutical partner research, Adaptive recently made available a new version of the ctDNA-based assay to assess MRD in DLBCL clinical trials. The research use only (RUO) assay has increased sensitivity to enable MRD assessment in clinical trials at the end of treatment timepoint (EOT) when disease burden is lowest as well as in post-treatment surveillance and later lines of therapy.お知らせ • Nov 12Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023Adaptive Biotechnologies Corporation updated revenue guidance for the full year 2023. The company is updating full year 2023 revenue guidance to exclude revenue from the Immune Medicine business. MRD business full year 2023 revenue to be in the range of $100 million to $105 million.お知らせ • Nov 03Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023Adaptive Biotechnologies Corporation announced that they will report Q3, 2023 results After-Market on Nov 09, 2023お知らせ • Sep 14Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQAdaptive Biotechnologies Corporation announced that clonoSEQ® is now available to health care providers as a fully integrated test in Aura, Epic’s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain in a patient’s body during and after treatment and that may eventually lead to recurrence of the disease. clonoSEQ is the only FDA-cleared test to detect MRD in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia. clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test. MRD is one of the strongest predictors of outcomes in blood cancers and routine testing provides a personalized way to track a patient’s individual response to treatment and inform clinical decision-making to optimize care. Under the partnership established in September 2022, clonoSEQ is available to healthcare providers through Aura, Epic's specialty diagnostics suite. Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.Board Change • Aug 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 05+ 1 more updateAdaptive Biotechnologies Corporation Announces Executive ChangesAdaptive Biotechnologies Corporation announced the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity. There are no disagreements or performance matters related to Mr. Sood's decision. His employment with the Company will end on or about August 15, 2023, and his position will not be replaced. Susan Bobulsky, who has led the clinical business for the past five years, will assume additional responsibilities and report directly to the Company's Chief Executive Officer, Chad Robins.お知らせ • Jul 12Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023Adaptive Biotechnologies Corporation announced that they will report Q2, 2023 results After-Market on Aug 02, 2023Board Change • Jul 07Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 15Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the BoardAdaptive Biotechnologies Corporation announced that Leslie Trigg submitted her resignation from the Board at its Annual Meeting held on June 9, 2023.お知らせ • Jun 03Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic CancerAdaptive Biotechnologies Corporation will be included in several oral and poster presentations investigating the clinical significance of minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as the European Hematology Association (EHA) Hybrid Congress taking place June 8-11 in Frankfurt, Germany. Data will be presented from clinical trials and real-world evidence studies using Adaptive's next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers. This assessment is performed as a series of tests in clinical trials and throughout a patient's cancer journey. The clonoSEQ Assay is the first and only NGS-MRD test authorized by the U.S. Food and Drug Administration (FDA) for MRD assessment in certain hematologic malignancies. Presentations will also highlight the value of utilizing NGS-MRD testing in clinical trials to assess the effectiveness of investigational, novel therapeutics. Multiple Myeloma: Oral Abstract 8001: Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma (pts): A phase 2 study with a safety run-in: 1:15-4:15 p.m. CDT: Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.お知らせ • May 10Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in OncologyAdaptive Biotechnologies Corporation announced that the U.S. Food and Drug Administration has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor (TCR) based T-Cell Therapy. This is the first TCR-based therapeutic product candidate to advance into clinical development based on Adaptive's collaboration with Genentech in oncology. Under the terms of Adaptive and Genentech's collaboration agreement, Genentech has responsibility for clinical, regulatory and commercialization efforts for any T-Cell Therapy product candidate. Adaptive reiterates its full year revenue guidance in the range of $205 to $215 million.お知らせ • May 05Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023Adaptive Biotechnologies Corporation provides revenue guidance for the full year 2023. The company reiterates full year 2023 revenue to be in the range of $205 million to $215 million.お知らせ • Feb 16Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023Adaptive Biotechnologies Corporation provided revenue guidance for full year 2023. For the period, the company expects revenue to be in the range of $205 million to $215 million.お知らせ • Jan 24Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023Adaptive Biotechnologies Corporation announced that they will report Q4, 2022 results After-Market on Feb 14, 2023Recent Insider Transactions • Aug 07Chief Commercial Officer of MRD recently sold €190k worth of stockOn the 5th of August, Nitin Sood sold around 18k shares on-market at roughly €10.81 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €522k more than they bought in the last 12 months.Reported Earnings • Aug 04Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in 2Q 2021)Second quarter 2022 results: US$0.37 loss per share (down from US$0.35 loss in 2Q 2021). Revenue: US$43.7m (up 13% from 2Q 2021). Net loss: US$52.0m (loss widened 5.6% from 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • May 06First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.29 loss in 1Q 2021)First quarter 2022 results: US$0.44 loss per share (down from US$0.29 loss in 1Q 2021). Revenue: US$38.6m (flat on 1Q 2021). Net loss: US$62.7m (loss widened 54% from 1Q 2021). Over the next year, revenue is forecast to grow 31%, compared to a 12% growth forecast for the industry in Germany.Recent Insider Transactions • Mar 10President recently sold €51k worth of stockOn the 7th of March, Julie Rubinstein sold around 5k shares on-market at roughly €11.06 per share. This was the largest sale by an insider in the last 3 months. This was Julie's only on-market trade for the last 12 months.Reported Earnings • Aug 05Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.26 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$38.5m (up 84% from 2Q 2020). Net loss: US$49.3m (loss widened 47% from 2Q 2020).Reported Earnings • May 07First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.25 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$38.4m (up 84% from 1Q 2020). Net loss: US$40.6m (loss widened 29% from 1Q 2020).Recent Insider Transactions • Apr 10Insider recently sold €128k worth of stockOn the 7th of April, R. Adams sold around 4k shares on-market at roughly €35.60 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.7m more than they bought in the last 12 months.Executive Departure • Mar 18Independent Director has left the companyOn the 17th of March, David Goel's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under David's name. A total of 3 executives have left over the last 12 months.Executive Departure • Mar 18Independent Director has left the companyOn the 17th of March, Eric Dobmeier's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eric's name. A total of 3 executives have left over the last 12 months.Is New 90 Day High Low • Mar 06New 90-day low: €36.40The company is down 9.0% from its price of €39.88 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 9.0% over the same period.Reported Earnings • Feb 25Full year 2020 earnings released: US$1.11 loss per share (vs US$1.01 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$98.4m (up 16% from FY 2019). Net loss: US$146.2m (loss widened 110% from FY 2019).Analyst Estimate Surprise Post Earnings • Feb 25Revenue beats expectationsRevenue exceeded analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 62%, compared to a 22% growth forecast for the Life Sciences industry in Germany.業績と収益の成長予測MUN:1HM - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028429-1755N/A512/31/2027352-3819-4812/31/2026287-72-17-4383/31/2026295-50-30-27N/A12/31/2025277-59-49-46N/A9/30/2025253-80-63-61N/A6/30/2025205-121-83-80N/A3/31/2025190-142-89-85N/A12/31/2024179-159-99-95N/A9/30/2024177-195-115-110N/A6/30/2024169-213-137-129N/A3/31/2024175-215-145-136N/A12/31/2023170-225-167-156N/A9/30/2023180-196-171-159N/A6/30/2023190-191-170-155N/A3/31/2023184-195-195-179N/A12/31/2022185-200-200-184N/A9/30/2022168-221-231-208N/A6/30/2022160-232-241-209N/A3/31/2022155-229-248-199N/A12/31/2021154-207-254-193N/A9/30/2021147-190-241-179N/A6/30/2021133-171-234-182N/A3/31/2021116-155-208-176N/A12/31/202098-146-168-150N/A9/30/202092-122-148-137N/A6/30/202092-99-131-120N/A3/31/202093-82-115-105N/A12/31/201985-70N/A205N/A9/30/201978-62N/A227N/A6/30/201969-56N/A245N/A3/31/201959-53N/A252N/A12/31/201856-46N/A-32N/A12/31/201738-43N/A-35N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1HM今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 1HM今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 1HM今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 1HMの収益 ( 15.2% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 1HMの収益 ( 15.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1HMの 自己資本利益率 は、3年後には低くなると予測されています ( 4.5 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/19 19:57終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Adaptive Biotechnologies Corporation 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Derik de BruinBofA Global ResearchMark MassaroBTIGWilliam BonelloCraig-Hallum Capital Group LLC10 その他のアナリストを表示
お知らせ • May 08+ 1 more updateAdaptive Biotechnologies Corporation Raises Revenue Guidance for the Full Year of 2026Adaptive Biotechnologies Corporation Raised revenue guidance for the full year of 2026. For the period, the company expects full year revenue for the MRD business to be between $260 million and $270 million, updated from the previous range between $255 million and $265 million.
お知らせ • Feb 06Adaptive Biotechnologies Corporation Provides Earnings Guidance for 2026Adaptive Biotechnologies Corporation provided earnings guidance for 2026. For the period, Adaptive Biotechnologies expects full year revenue for the MRD business to be between $255 millionand $265 million. No revenue guidance is provided for the Immune Medicine business.
お知らせ • Nov 06Adaptive Biotechnologies Corporation Updates Earnings Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updates earnings guidance for the full year 2025. The company expected full year revenue for the MRD business to be between $202 million and $207 million, updated from the previous range between $190 million and $200 million. No revenue guidance is provided for the Immune Medicine business.
お知らせ • Aug 06Adaptive Biotechnologies Corporation Updates Financial Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updated financial guidance for the full year 2025. For the year, the company expects full year revenue for the MRD business to be between $190 million and $200 million, updated from the previous range between $180 million and $190 million. No revenue guidance is provided for the Immune Medicine busine.
お知らせ • May 02Adaptive Biotechnologies Corporation Revises Earnings Guidance for 2025Adaptive Biotechnologies Corporation revised earnings guidance for 2025. For the period, the company expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.
お知らせ • Apr 03Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
Board Change • Jun 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 30Adaptive Biotechnologies Corporation Reports New Data Reinforcing Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and ResearchAdaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO and EHA this year continue to reinforce clonoSEQ’s role in modern hematologic oncology care — as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Across hematologic malignancies, these studies highlight how MRD measured by clonoSEQ continues to be broadly incorporated into both research and clinical practice: Multiple myeloma: Highly sensitive MRD testing continues to demonstrate depth and durability of response across novel therapies, including follow-up data from the inMMyCAR trial of CAR T-cell therapy and bispecific antibody data from MONUMENTAL-3. In addition, a final analysis from the CEPHEUS trial, the basis for the first-ever FDA approval based on an MRD endpoint, showed higher rates of sustained MRD negativity in patients treated with quadruplet regimen daratumumab plus VRd (bortezomib, lenalidomide, and dexamethasone). Chronic lymphocytic leukemia (CLL): MRD is being incorporated into decisions around therapy duration and discontinuation in studies including BOVen-?MRD400 and venetoSTOP, the latter demonstrating that personalized venetoclax treatment duration based on uMRD5 status leads to durable treatment-free remissions. Acute lymphoblastic leukemia (ALL): In a Phase 2 study evaluating dose-adjusted EPOCH with rituximab and tafasitamab, MRD assessment with clonoSEQ continues to outperform flow cytometry in detecting residual disease and predicting patient outcomes and can be used to assess disease burden in cerebrospinal fluid. Lymphoma: clonoSEQ leverages sensitivity and specificity to support MRD testing in real-world and clinical trial settings across multiple major lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). At EHA this year, new data further expand the evidence base for highly sensitive, next-generation sequencing–based MRD assessment and underscore the increasingly global nature of clonoSEQ’s reach and impact. Across Europe, growing momentum behind MRD-guided care is being driven, in part, by increasing biopharmaceutical industry investment in interventional studies that incorporate MRD into treatment decisions. clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL. clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR).
お知らせ • May 08+ 1 more updateAdaptive Biotechnologies Corporation Raises Revenue Guidance for the Full Year of 2026Adaptive Biotechnologies Corporation Raised revenue guidance for the full year of 2026. For the period, the company expects full year revenue for the MRD business to be between $260 million and $270 million, updated from the previous range between $255 million and $265 million.
お知らせ • Apr 27Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 05, 2026Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 05, 2026.
お知らせ • Apr 16Adaptive Biotechnologies Corporation to Report Q1, 2026 Results on May 05, 2026Adaptive Biotechnologies Corporation announced that they will report Q1, 2026 results After-Market on May 05, 2026
お知らせ • Feb 06Adaptive Biotechnologies Corporation Provides Earnings Guidance for 2026Adaptive Biotechnologies Corporation provided earnings guidance for 2026. For the period, Adaptive Biotechnologies expects full year revenue for the MRD business to be between $255 millionand $265 million. No revenue guidance is provided for the Immune Medicine business.
お知らせ • Jan 23Adaptive Biotechnologies Corporation to Report Q4, 2025 Results on Feb 05, 2026Adaptive Biotechnologies Corporation announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 05, 2026
Board Change • Jan 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Dec 13Independent Director recently sold €316k worth of stockOn the 10th of December, Robert Hershberg sold around 23k shares on-market at roughly €13.74 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.1m more than they bought in the last 12 months.
Board Change • Dec 08Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 06Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual MeetingAdaptive Biotechnologies Corporation announced growing interventional use of its clonoSEQ test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive's clonoSEQ test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care. The presentations below show how investigators are applying clonoSEQ MRD results to tailor treatment intensity or duration with greater precision. Multiple Myeloma (MM). A total of 32 abstracts will be presented (31 MM, one smoldering MM), with a focus on MRD assessment of treatment response, real-world data demonstrating the link between MRD status and clinical outcomes, and several studies describing how clonoSEQ MRD Results are being used to guide treatment decisions. A presentation focused on MRD dynamics in the phase III AURIGA study of 200 newly diagnosed MM patients demonstrated that deep MRD responses and sustained MRD negativity correlated with improved progression free survival. The study shows that use of intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates (oral presentation, abstract 97). Non-Hodgkin Lymphoma (NHL). Fifteen abstracts in NHL will be presented, focusing on use of MRD to better understand depth of response and to guide therapy.
Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.063 (vs US$0.22 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.063 (up from US$0.22 loss in 3Q 2024). Revenue: US$94.0m (up 102% from 3Q 2024). Net income: US$9.55m (up US$41.6m from 3Q 2024). Profit margin: 10% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 06Adaptive Biotechnologies Corporation Updates Earnings Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updates earnings guidance for the full year 2025. The company expected full year revenue for the MRD business to be between $202 million and $207 million, updated from the previous range between $190 million and $200 million. No revenue guidance is provided for the Immune Medicine business.
Board Change • Oct 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 16Adaptive Biotechnologies Corporation to Report Q3, 2025 Results on Nov 05, 2025Adaptive Biotechnologies Corporation announced that they will report Q3, 2025 results After-Market on Nov 05, 2025
お知らせ • Aug 06Adaptive Biotechnologies Corporation Updates Financial Guidance for the Full Year 2025Adaptive Biotechnologies Corporation updated financial guidance for the full year 2025. For the year, the company expects full year revenue for the MRD business to be between $190 million and $200 million, updated from the previous range between $180 million and $190 million. No revenue guidance is provided for the Immune Medicine busine.
お知らせ • Jul 16Adaptive Biotechnologies Corporation to Report Q2, 2025 Results on Aug 05, 2025Adaptive Biotechnologies Corporation announced that they will report Q2, 2025 results After-Market on Aug 05, 2025
お知らせ • Jun 30+ 5 more updatesAdaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 3000E Value IndexAdaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell 3000E Value Index
お知らせ • May 30Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid CancersAdaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ®? test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. Data to be presented at ASCO: Presentation Type and Number Title Presentation Timing B-Cell Acute Lymphoblastic Leukemia. Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, Sunday, June 1, 6540 cyclophosphamide, and doxorubicin (DA-EPOCH) + rituximab (R) + tafasitamab (tafa) for adults 9 a.m.-12 p.m. CDT with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL). Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute Sunday, June 1, 6543 lymphoblastic leukemia 9 a.m.-12p.m. CDT Multiple Myeloma: Multiple Myeloma: Primary endpoints of Tuesday, June 3, 7501 lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple.
お知らせ • May 02Adaptive Biotechnologies Corporation Revises Earnings Guidance for 2025Adaptive Biotechnologies Corporation revised earnings guidance for 2025. For the period, the company expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.
お知らせ • Apr 30Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025. Location: entirely via the internet, United States
お知らせ • Apr 11Adaptive Biotechnologies Corporation to Report Q1, 2025 Results on May 01, 2025Adaptive Biotechnologies Corporation announced that they will report Q1, 2025 results After-Market on May 01, 2025
お知らせ • Mar 11Adaptive Biotechnologies Corporation Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell LymphomaAdaptive Biotechnologies Corporation announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. The assay leverages the same powerful technology as prior versions, detecting MRD by reading the full immune receptor sequence of the malignant B cells rather than relying on individual point mutations. Maintaining this proprietary approach enables improvements in sensitivity while preserving the exquisite specificity that minimizes risk of overtreatment due to false positives. The enhanced assay was previously made available for research use in November 2023 and is already being incorporated into both biopharma-sponsored and investigator-initiated prospective trials. Data generated using this assay and presented at ASH 2024 by Bond and colleagues demonstrated that in patients for which MRD was assessed by clonoSEQ, MRD negativity post-cycle six was highly prognostic of progression-free survival. clonoSEQ is the first and only DLBCL MRD test available for clinical use. Having secured Medicare coverage for clonoSEQ in DLBCL in July of 2022, Adaptive has since provided MRD testing for more than 2,800 DLBCL patients and was used to manage and inform patient care by over 640 providers in 2024 alone. The New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) recently approved the enhanced version of the clonoSEQ ctDNA assay for the detection and monitoring of MRD in patients with DLBCL. This comes on the heels of the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas, which included language recommending ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of first-line treatment. Because DLBCL outcomes can vary widely following frontline treatment, the ability of MRD results to accurately risk stratify patients in this setting is critical, as an MRD test can help clinicians differentiate a likely cure from an impending relapse. As the number of clinical trials in DLBCL exploring novel MRD-directed treatment consolidation strategies to reduce relapse rates grows, the role for clonoSEQ as a highly sensitive and specific ctDNA-based test will continue to expand.
お知らせ • Jan 23Adaptive Biotechnologies Corporation to Report Q4, 2024 Results on Feb 11, 2025Adaptive Biotechnologies Corporation announced that they will report Q4, 2024 results After-Market on Feb 11, 2025
Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 09Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in Mrd Testing with Clonoseq and Its Impact on Blood Cancer Treatment DecisionsAdaptive Biotechnologies Corporation announced new data demonstrating the impact of measurable residual disease assessment using Adaptive’s next-generation sequencing-based clonoSEQ test in blood cancer clinical care and drug development. The data are featured in more than 65 abstracts being presented at the 66th Annual Meeting of the American Society of Hematology, taking place December 6-10 in San Diego. Phase 3 data from the ECOG-ACRIN EA4151 trial indicate that autologous hematopoietic cell transplantation (auto-HCT) may not provide additional benefit for mantle cell lymphoma patients in first complete remission who have undetectable minimal residual disease at a sensitivity of 10?6. The findings will be presented in a late-breaking abstract titled, Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma Patients (pts) in First Complete Remission with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial (Abstract LBA6). Patients in CR with uMRD at 10?6 sensitivity from peripheral blood were randomized to receive either auto-HCT plus three years of maintenance rituximab or MR alone. Interim analysis, with a median follow-up of 2.7 years, showed no significant difference in overall survival between the two groups, suggesting that auto-HCT may be unnecessary for patients achieving deep remission as measured by highly sensitive MRD assessment. Data from the FELIX study indicate that achieving deep molecular remission, defined as MRD levels below 10?6, correlates with improved outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel. These findings were presented in an oral session titled Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes (Abstract 963). The study found that 84% of treatment responders who had a clonoSEQ MRD test, achieved MRD <10?6. This result was associated with more durable responses, and higher event-free survival and OS rates than those observed in patients with MRD =10-4 and between 10-4 and 10-6. Additional Key clonoSEQ Data Presented at the Meeting: Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731 (Abstract1). This Phase 3 randomized trial evaluated the addition of blinatumomab to standard chemotherapy in pediatric patients with newly diagnosed standard-risk B-ALL with average or higher risk of relapse. In the SR average cohort, patients that were MRD positive by clonoSEQ were randomized to receive standard chemotherapy with or without blinatumomab. The study found that incorporating blinatumomab significantly improved disease-free survival compared to chemotherapy alone, establishing a new treatment standard for this patient population. Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation (Abstract 363). This study identified 49 newly diagnosed multiple myeloma patients treated with a quadruplet regimen followed by autologous stem cell transplantation who experienced MRD progression as assessed by clonoSEQ, or disease progression as defined by the International Myeloma Working Group. The median time from MRD progression to IMWG-defined disease progression was 10.1 months, supporting that rising MRD levels are an early indicator of impending clinical relapse in MM patients. Minimal Residual Disease-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (Abstract 1010). This Phase 2 study evaluating the use of venetoclax and obinutuzumab in treatment-naïve CLL patients found that those achieving undetectable MRD (<10?6) after nine cycles could discontinue therapy early. These patients had progression-free survival comparable to those who completed the standard 12 cycles, demonstrating the feasibility of MRD-guided treatment duration to minimize therapy exposure without compromising efficacy.
お知らせ • Oct 10Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024Adaptive Biotechnologies Corporation announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
お知らせ • Aug 29Adaptive Announces IVDR Certification for clonoSEQ® in European UnionAdaptive Biotechnologies Corporation announced that clonoSEQ® has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). The medical diagnostics field has experienced significant technological advancement in recent years, leading the EU to replace its previous regulatory framework, the In Vitro Diagnostics Directive (IVDD), with a more stringent set of standards for quality and safety, known as IVDR. Adaptive worked with EU notified body BSI to complete the certification process and transition the company’s IVDD CE-marked product, the clonoSEQ Assay B-Cell Reagent Set, to this new regulation. clonoSEQ is now the first and only test to receive IVDR certification for the detection of minimal residual disease (MRD) in lymphoid malignancies. clonoSEQ’s intended use under IVDR is broad in scope, allowing for assessment of MRD status and changes in disease burden during and after treatment in patients diagnosed with B-cell malignancies. As MRD testing becomes increasingly adopted in patient care, clonoSEQ provides a powerful and dynamic way to measure risk status for patients with lymphoid malignancies and yields real-time insights into disease progression that can help oncologists provide a more personalized treatment approach. In addition to clinical use, clonoSEQ is the test of choice for MRD assessment among drug developers performing clinical research in hematologic malignancies. The assay has been included in global, label-enabling studies for a multitude of therapies approved by the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) over the past several years. IVDR certification allows Adaptive to meet the clinical trial regulations for testing EU subjects’ samples, and sponsors can seamlessly send clinical trial subjects’ samples from the EU to Adaptive’s Seattle, Washington laboratory. clonoSEQ is well-established as a leading tool in blood cancer MRD assessment, supported by more than 150 peer-reviewed publications and used clinically by more than 3,700 clinicians over the past year. Furthermore, clonoSEQ MRD is currently being utilized in more than 160 active biopharma-sponsored trials. clonoSEQ is available locally in the EU to oncologists through technology transfer partnerships with major academic laboratories. clonoSEQ testing can currently be performed in France by Centre Hospitalier Universitaire (CHU) Toulouse, in Italy by Hospital of Bologna, in Spain by Hospital 12 du Octubre, and in Germany by HPH laboratory. Additional technology transfer partnerships are expected to launch in the EU and surrounding markets later in 2024.
Board Change • Aug 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 12Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024Adaptive Biotechnologies Corporation announced that they will report Q2, 2024 results After-Market on Aug 01, 2024
お知らせ • Apr 28Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024, at 09:00 Pacific Standard Time. Agenda: To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders. The two nominees for election to the board of directors are Peter Neupert and Michelle Griffin; to approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement; to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; and to conduct any other business properly brought before the meeting or any adjournments thereof.
お知らせ • Apr 19Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024Adaptive Biotechnologies Corporation announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Apr 04Adaptive Biotechnologies Corporation Announces CFO ChangesAdaptive Biotechnologies Corporation announced that Tycho Peterson will depart the company as CFO. Kyle Piskel, the company's Principal Accounting Officer, will succeed Peterson as full-time CFO. Piskel served as the company's interim CFO from February to June 2022.
お知らせ • Apr 03Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
お知らせ • Jan 30Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024Adaptive Biotechnologies Corporation announced that they will report Q4, 2023 results After-Market on Feb 14, 2024
お知らせ • Dec 05Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual MeetingAdaptive Biotechnologies Corporation together with its collaborators will present data from more than 30 abstracts demonstrating the actionability of Adaptive's next-generation sequencing (NGS)-based clonoSEQ test in assessing minimal residual disease (MRD) in blood cancer patients at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California. clonoSEQ is the only U.S. Food and Drug Administration (FDA)-cleared test to detect MRD in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ testing for other lymphoid malignancies, includingdiffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL) is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, Washington. Minimal residual disease – also referred to as measurable residual disease – is one of the strongest predictors of outcomes in blood cancers and routine testing provides a personalized way to track a patient’s individual response to treatment and inform shared decision-making to optimize care. In addition to clinical use, MRD testing is widely used in drug development to get an early read on efficacy to inform patient stratification and increasingly as a trial endpoint. Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured in a late-breaking presentation, eight oral presentations and 24 posters across lymphoid malignancies. Studies will be presented demonstrating the clinical actionability of MRD testing across disease states. Notably, data illustrating the prognostic value of clonoSEQ MRD assessment using peripheral blood in MM and from circulating tumor DNA (ctDNA) in DLBCL will also be presented. Additionally, biopharmaceutical companies and other investigators will share data from 13 studies using clonoSEQ as an endpoint to measure deep responses during or after therapy, including novel treatment regimens such as CAR T-cell therapies and bispecifics. To advance biopharmaceutical partner research, Adaptive recently made available a new version of the ctDNA-based assay to assess MRD in DLBCL clinical trials. The research use only (RUO) assay has increased sensitivity to enable MRD assessment in clinical trials at the end of treatment timepoint (EOT) when disease burden is lowest as well as in post-treatment surveillance and later lines of therapy.
お知らせ • Nov 12Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023Adaptive Biotechnologies Corporation updated revenue guidance for the full year 2023. The company is updating full year 2023 revenue guidance to exclude revenue from the Immune Medicine business. MRD business full year 2023 revenue to be in the range of $100 million to $105 million.
お知らせ • Nov 03Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023Adaptive Biotechnologies Corporation announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
お知らせ • Sep 14Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQAdaptive Biotechnologies Corporation announced that clonoSEQ® is now available to health care providers as a fully integrated test in Aura, Epic’s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain in a patient’s body during and after treatment and that may eventually lead to recurrence of the disease. clonoSEQ is the only FDA-cleared test to detect MRD in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia. clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test. MRD is one of the strongest predictors of outcomes in blood cancers and routine testing provides a personalized way to track a patient’s individual response to treatment and inform clinical decision-making to optimize care. Under the partnership established in September 2022, clonoSEQ is available to healthcare providers through Aura, Epic's specialty diagnostics suite. Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.
Board Change • Aug 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 05+ 1 more updateAdaptive Biotechnologies Corporation Announces Executive ChangesAdaptive Biotechnologies Corporation announced the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity. There are no disagreements or performance matters related to Mr. Sood's decision. His employment with the Company will end on or about August 15, 2023, and his position will not be replaced. Susan Bobulsky, who has led the clinical business for the past five years, will assume additional responsibilities and report directly to the Company's Chief Executive Officer, Chad Robins.
お知らせ • Jul 12Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023Adaptive Biotechnologies Corporation announced that they will report Q2, 2023 results After-Market on Aug 02, 2023
Board Change • Jul 07Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Katey Owen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 15Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the BoardAdaptive Biotechnologies Corporation announced that Leslie Trigg submitted her resignation from the Board at its Annual Meeting held on June 9, 2023.
お知らせ • Jun 03Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic CancerAdaptive Biotechnologies Corporation will be included in several oral and poster presentations investigating the clinical significance of minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as the European Hematology Association (EHA) Hybrid Congress taking place June 8-11 in Frankfurt, Germany. Data will be presented from clinical trials and real-world evidence studies using Adaptive's next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers. This assessment is performed as a series of tests in clinical trials and throughout a patient's cancer journey. The clonoSEQ Assay is the first and only NGS-MRD test authorized by the U.S. Food and Drug Administration (FDA) for MRD assessment in certain hematologic malignancies. Presentations will also highlight the value of utilizing NGS-MRD testing in clinical trials to assess the effectiveness of investigational, novel therapeutics. Multiple Myeloma: Oral Abstract 8001: Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma (pts): A phase 2 study with a safety run-in: 1:15-4:15 p.m. CDT: Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
お知らせ • May 10Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in OncologyAdaptive Biotechnologies Corporation announced that the U.S. Food and Drug Administration has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor (TCR) based T-Cell Therapy. This is the first TCR-based therapeutic product candidate to advance into clinical development based on Adaptive's collaboration with Genentech in oncology. Under the terms of Adaptive and Genentech's collaboration agreement, Genentech has responsibility for clinical, regulatory and commercialization efforts for any T-Cell Therapy product candidate. Adaptive reiterates its full year revenue guidance in the range of $205 to $215 million.
お知らせ • May 05Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023Adaptive Biotechnologies Corporation provides revenue guidance for the full year 2023. The company reiterates full year 2023 revenue to be in the range of $205 million to $215 million.
お知らせ • Feb 16Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023Adaptive Biotechnologies Corporation provided revenue guidance for full year 2023. For the period, the company expects revenue to be in the range of $205 million to $215 million.
お知らせ • Jan 24Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023Adaptive Biotechnologies Corporation announced that they will report Q4, 2022 results After-Market on Feb 14, 2023
Recent Insider Transactions • Aug 07Chief Commercial Officer of MRD recently sold €190k worth of stockOn the 5th of August, Nitin Sood sold around 18k shares on-market at roughly €10.81 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €522k more than they bought in the last 12 months.
Reported Earnings • Aug 04Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in 2Q 2021)Second quarter 2022 results: US$0.37 loss per share (down from US$0.35 loss in 2Q 2021). Revenue: US$43.7m (up 13% from 2Q 2021). Net loss: US$52.0m (loss widened 5.6% from 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.29 loss in 1Q 2021)First quarter 2022 results: US$0.44 loss per share (down from US$0.29 loss in 1Q 2021). Revenue: US$38.6m (flat on 1Q 2021). Net loss: US$62.7m (loss widened 54% from 1Q 2021). Over the next year, revenue is forecast to grow 31%, compared to a 12% growth forecast for the industry in Germany.
Recent Insider Transactions • Mar 10President recently sold €51k worth of stockOn the 7th of March, Julie Rubinstein sold around 5k shares on-market at roughly €11.06 per share. This was the largest sale by an insider in the last 3 months. This was Julie's only on-market trade for the last 12 months.
Reported Earnings • Aug 05Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.26 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$38.5m (up 84% from 2Q 2020). Net loss: US$49.3m (loss widened 47% from 2Q 2020).
Reported Earnings • May 07First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.25 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$38.4m (up 84% from 1Q 2020). Net loss: US$40.6m (loss widened 29% from 1Q 2020).
Recent Insider Transactions • Apr 10Insider recently sold €128k worth of stockOn the 7th of April, R. Adams sold around 4k shares on-market at roughly €35.60 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.7m more than they bought in the last 12 months.
Executive Departure • Mar 18Independent Director has left the companyOn the 17th of March, David Goel's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under David's name. A total of 3 executives have left over the last 12 months.
Executive Departure • Mar 18Independent Director has left the companyOn the 17th of March, Eric Dobmeier's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eric's name. A total of 3 executives have left over the last 12 months.
Is New 90 Day High Low • Mar 06New 90-day low: €36.40The company is down 9.0% from its price of €39.88 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 9.0% over the same period.
Reported Earnings • Feb 25Full year 2020 earnings released: US$1.11 loss per share (vs US$1.01 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$98.4m (up 16% from FY 2019). Net loss: US$146.2m (loss widened 110% from FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 25Revenue beats expectationsRevenue exceeded analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 62%, compared to a 22% growth forecast for the Life Sciences industry in Germany.